Trial Profile
Daily Antiretroviral Therapy (DART 1): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Didanosine Enteric Coated (Ddl-EC) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected Patients
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Didanosine (Primary) ; Efavirenz; Lamivudine
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DART-I
- Sponsors Bristol-Myers Squibb
- 08 Jun 2009 New trial record.